Abstract

SARS-CoV-2 infection and the subsequent development of the COVID-19 pandemic, as is known, particularly affected certain segments of the population, respectively a series of systems and organs such as the lungs, kidneys, liver, heart and brain, which were identified as priority organs. Liver diseases are considered a particular risk factor for the high mortality caused by the COVID-19 pandemic. In addition, liver damage, which previously coexisted with a chronic pathology, was demonstrated in a substantial proportion of patients with SARS-COV-2 infection, respectively COVID-19 disease, especially in those with severe clinical symptoms. Also added are antiviral drugs, immunosuppressive drugs after liver transplantation, pre-existing liver diseases and chronic liver diseases such as cirrhosis, which have been implicated in the development of liver damage induced by viral infection. As a result, some precautions have been taken to prevent, monitor the virus and avoid immunocompromised and susceptible people, such as those with chronic liver disease, from being infected with SARS-CoV-2, thus avoiding the increase in mortality in this category of patients. The aim of this analysis was to examine the liver damage caused by SARS-CoV-2 infection and the clinical-biological implications during the pandemic on the range of morbidity and mortality and, therefore, the possibility of developing preventive measures in patients with chronic liver pathology.

Keywords:Liver; Hepatic disorders; SARS-COV 2 infections; COVID-19